WO2025079538A1 - 網膜色素上皮細胞の保護剤 - Google Patents

網膜色素上皮細胞の保護剤 Download PDF

Info

Publication number
WO2025079538A1
WO2025079538A1 PCT/JP2024/035711 JP2024035711W WO2025079538A1 WO 2025079538 A1 WO2025079538 A1 WO 2025079538A1 JP 2024035711 W JP2024035711 W JP 2024035711W WO 2025079538 A1 WO2025079538 A1 WO 2025079538A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
acid sequence
amino acid
terminus
retinal pigment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2024/035711
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
拓 尾▲崎▼
哲郎 山下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iwate University NUC
Original Assignee
Iwate University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iwate University NUC filed Critical Iwate University NUC
Priority to JP2025551481A priority Critical patent/JP7832745B2/ja
Publication of WO2025079538A1 publication Critical patent/WO2025079538A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Definitions

  • the present invention relates to a protective agent for retinal pigment epithelial cells.
  • Age-related macular degeneration AMD is one of the most common age-related eye diseases. The number of patients worldwide is approximately 170 million, and the number of patients is expected to continue to increase. There are two types of AMD: exudative (wet) AMD and atrophic (dry) AMD. Although the mechanisms of onset are different, in both cases, functional damage to the retinal pigment epithelium (RPE) cells present in the lower part of the macula causes a decrease in vision.
  • RPE retinal pigment epithelium
  • Patent Document 1 reports that (S)-4-fluoro-5-(2-methyl-1,4-diazepan-1-ylsulfonyl)isoquinoline has a protective effect on retinal pigment epithelial cells.
  • a method for preventing and treating age-related macular degeneration by protecting retinal pigment epithelial cells has not yet been established, and the search for new components that have a protective effect on retinal pigment epithelial cells is still significant.
  • the present invention aims to provide a protective agent for retinal pigment epithelial cells that is useful for preventing and treating age-related macular degeneration.
  • the protective agent for retinal pigment epithelial cells of the present invention developed based on the above findings, has as its active ingredient, as described in claim 1, a peptide having an inhibitory effect on mitochondrial calpain and a protein transduction domain added to the N-terminus of the peptide.
  • the protective agent for retinal pigment epithelial cells according to claim 2 is the protective agent for retinal pigment epithelial cells according to claim 1, wherein the peptide having an inhibitory effect against mitochondrial calpain is (a) a peptide consisting of the amino acid sequence (PDALKSRTJR) shown in SEQ ID NO: 1 (J is L or I); (b) a peptide consisting of an amino acid sequence in which up to five amino acids have been added to the N-terminus and/or C-terminus of the amino acid sequence shown in SEQ ID NO: 1, and which has an inhibitory effect on mitochondrial calpain; or (c) a peptide consisting of an amino acid sequence in which up to two amino acids at the N-terminus and/or C-terminus of the amino acid sequence shown in SEQ ID NO: 1 have been replaced with other amino acids or deleted, and which has an inhibitory effect on mitochondrial calpain.
  • the peptide having an inhibitory effect against mitochondrial calpain is (a) a
  • the protective agent for retinal pigment epithelial cells according to claim 3 is the protective agent for retinal pigment epithelial cells according to claim 1, wherein the protein transduction domain is a peptide consisting of at least a part of the amino acid sequence of the transduction site of HIV-1 Tat.
  • the preventive and/or therapeutic agent for age-related macular degeneration of the present invention has as an active ingredient a peptide having an inhibitory effect on mitochondrial calpain and a protein transduction domain added to the N-terminus of the peptide.
  • the present invention provides a protective agent for retinal pigment epithelial cells that is useful for preventing and treating age-related macular degeneration.
  • Example 1 shows tissue photographs of retinal sections showing that the retinal pigment epithelium cell layer is protected by instilling 20 mM Tat- ⁇ CL peptide in the eyes in an experiment using age-related macular degeneration model mice in Example 1.
  • 11 is a graph showing that an increase in the number of deposits derived from the retinal pigment epithelium cell layer is suppressed.
  • 11 is a graph showing that thinning of the retinal photoreceptor layer is suppressed.
  • 1 is a tissue photograph of a retinal section showing that the retinal pigment epithelium cell layer is protected by instilling 2 mM Tat- ⁇ CL peptide in the eye in an experiment using age-related macular degeneration model mice in Example 2.
  • 11 is a graph showing that an increase in the number of deposits derived from the retinal pigment epithelium cell layer is suppressed.
  • 11 is a graph showing that thinning of the retinal photoreceptor layer is suppressed.
  • 13 is a tissue photograph of a retinal section showing that the retinal pigment epithelium cell layer is protected by instilling 200 ⁇ M Tat- ⁇ CL peptide in the eye in an experiment using age-related macular degeneration model mice in Example 3.
  • 11 is a graph showing that an increase in the number of deposits derived from the retinal pigment epithelium cell layer is suppressed.
  • 11 is a graph showing that thinning of the retinal photoreceptor layer is suppressed.
  • the protective agent for retinal pigment epithelial cells of the present invention contains as an active ingredient a peptide having an inhibitory effect on mitochondrial calpain and a protein transduction domain added to the N-terminus.
  • the peptide having an inhibitory effect on mitochondrial calpain and a protein transduction domain added to the N-terminus is a peptide that the present inventors' research group reported in Patent No. 6183879 to have a protective effect on retinal photoreceptor cells.
  • a peptide having an inhibitory effect on mitochondrial calpain in a peptide having an inhibitory effect on mitochondrial calpain which is a peptide having an amino acid sequence (PDALKSRTJR) shown in SEQ ID NO: 1 (J is L or I).
  • a peptide having an amino acid sequence in which J is L is included in the amino acid sequence of domain III of the active subunit of rat ⁇ -calpain (also called CAPN1 or ⁇ CL) identified by accession number: NP_062025.1.
  • Domain III of the active subunit of ⁇ -calpain is a functional domain also called the C2L (C2-like) domain.
  • a peptide having an amino acid sequence in which J is I is included in the amino acid sequence of domain III of the active subunit of human ⁇ -calpain identified by accession number: NP_005177.
  • the peptide having an inhibitory effect on mitochondrial calpain in a peptide having an inhibitory effect on mitochondrial calpain which is obtained by adding a protein transduction domain to the N-terminus of the peptide having an inhibitory effect on mitochondrial calpain, may be a peptide having an amino acid sequence in which up to five amino acids have been added to the N-terminus and/or C-terminus of the amino acid sequence shown in SEQ ID NO: 1, and having an inhibitory effect on mitochondrial calpain.
  • Specific examples thereof include a peptide having an amino acid sequence in which up to five amino acids have been added to the N-terminus of the amino acid sequence shown in SEQ ID NO: 1 (e.g., a peptide consisting of the amino acid sequence shown in SEQ ID NO: 2), a peptide having an amino acid sequence in which up to five amino acids have been added to the C-terminus of the amino acid sequence shown in SEQ ID NO: 1 (e.g., a peptide consisting of the amino acid sequence shown in SEQ ID NO: 3), a peptide having an amino acid sequence in which up to five amino acids have been added to each of the N-terminus and C-terminus of the amino acid sequence shown in SEQ ID NO: 1 (e.g., a peptide consisting of the amino acid sequence shown in SEQ ID NO: 4), and the like.
  • the peptide having an inhibitory effect on mitochondrial calpain in a peptide having a protein transduction domain added to the N-terminus of the peptide having an inhibitory effect on mitochondrial calpain may be a peptide having an amino acid sequence in which up to two amino acids at the N-terminus and/or C-terminus of the amino acid sequence shown in SEQ ID NO: 1 have been replaced with other amino acids or deleted, and having an inhibitory effect on mitochondrial calpain.
  • the protein transduction domain (PTD) added to the N-terminus of a peptide that has an inhibitory effect on mitochondrial calpain can be a known cell-penetrating peptide that has the ability to pass not only the peptide itself but also other compounds such as oligonucleotides, peptides, proteins, and oligosaccharides that are bound to it through the bilayer of cell membrane phospholipids.
  • peptides consisting of at least a portion of the amino acid sequence of the HIV-1 Tat transduction site, peptides consisting of 3 to 12 arginines, peptides consisting of 3 to 12 lysines, peptides consisting of 3 to 16 histidines, PEP-1 peptide, ANTP, VP22 protein, etc. (see, if necessary, Morris et al., Nat. Biotechnol., 19:1173-1175, 2001; Schwarze et al., Trends Cell Biol., 10:290-295, 2000; Vives et al., J. Biol. Chem., 272:16010-16017, 1997, etc.).
  • Examples of protein transduction domains that are desirable to add to the N-terminus of a peptide that has an inhibitory effect on mitochondrial calpain include a peptide consisting of the amino acid sequence shown in SEQ ID NO: 5, which corresponds to amino acid sequence 49-57 of the transduction site of HIV-1 Tat, a peptide consisting of an amino acid sequence in which one or several amino acids have been substituted, deleted, and/or added in the amino acid sequence shown in SEQ ID NO: 5 (the number of substitutions and deletions is a maximum of 5, and the number of additions is a maximum of 10), and which has the effect of allowing not only itself but also other compounds such as oligonucleotides, peptides, proteins, and oligosaccharides bound to it to pass through the bilayer of cell membrane phospholipids, and a peptide consisting of 3 to 16 histidines.
  • a peptide having an inhibitory effect on mitochondrial calpain and a protein transduction domain added to the N-terminus of the peptide can be prepared by a method known per se, for example, chemical synthesis using a peptide synthesizer, or by genetic engineering techniques.
  • a peptide having an inhibitory effect on mitochondrial calpain and a protein transduction domain added to the N-terminus has an excellent protective effect on retinal pigment epithelial cells, and is therefore useful for the prevention and treatment of age-related macular degeneration, in which functional damage to retinal pigment epithelial cells is a cause of reduced vision.
  • the peptide can be formulated in a form suitable for the administration method by a method known per se, but it is preferable that the formulation be a non-invasive eye drop.
  • the eye drops can be prepared by mixing various additives such as buffers, solubilizers, isotonicity agents, stabilizers, preservatives, viscosity agents, chelating agents, pH adjusters, and cooling agents with a solvent, and then aseptically filtering the mixture in a sterile environment and filling the mixture into a suitable sterilized container.
  • additives such as buffers, solubilizers, isotonicity agents, stabilizers, preservatives, viscosity agents, chelating agents, pH adjusters, and cooling agents.
  • buffers include boric acid and its salts (such as borax), citric acid and its salts (such as sodium citrate), phosphoric acid and its salts (such as sodium monohydrogen phosphate), tartaric acid and its salts (such as sodium tartrate), gluconic acid and its salts (such as sodium gluconate), acetic acid and its salts (such as sodium acetate), various amino acids, and combinations of these.
  • boric acid and its salts such as borax
  • citric acid and its salts such as sodium citrate
  • phosphoric acid and its salts such as sodium monohydrogen phosphate
  • tartaric acid and its salts such as sodium tartrate
  • gluconic acid and its salts such as sodium gluconate
  • acetic acid and its salts such as sodium acetate
  • various amino acids such as sodium acetate
  • solubilizing agent examples include polyoxyethylene hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 60, etc.), polyethylene glycol (macrogol 4000, etc.), polyoxyethylene sorbitan higher fatty acid ester (polysorbate 80, etc.), polyoxyethylene (POE)-polyoxypropylene (POP) block copolymer (poloxamer 407, etc.), and propylene glycol.
  • polyoxyethylene hydrogenated castor oil polyoxyethylene hydrogenated castor oil 60, etc.
  • polyethylene glycol polyethylene glycol (macrogol 4000, etc.)
  • polyoxyethylene sorbitan higher fatty acid ester polysorbate 80, etc.
  • POE polyoxyethylene-polyoxypropylene
  • POP polyoxypropylene block copolymer
  • propylene glycol examples include inorganic salts (sodium chloride, potassium chloride, calcium chloride, etc.), sugars (mannitol, glucose, etc.), and polyhydric alcohols
  • the stabilizer include sodium edetate, cyclodextrin, sulfite, citric acid and its salts, and butylhydroxytoluene.
  • preservatives include benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorobutanol, sorbic acid, potassium sorbate, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, polyquartenium-1, polyaminopropyl biguanide, alkylaminoethyl glycine hydrochloride, cetylpyridinium chloride, and thimerosal.
  • thickening agents include polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, hydroxyethyl cellulose, hydroxypropyl methylcellulose, methylcellulose, sodium chondroitin sulfate, sodium hyaluronate, carboxymethyl cellulose, and carboxyvinyl polymer.
  • chelating agents include sodium edetate and sodium citrate.
  • pH adjusters include hydrochloric acid, citric acid and its salts, boric acid and its salts, phosphoric acid and its salts, acetic acid and its salts, tartaric acid and its salts, sodium hydroxide, potassium hydroxide, sodium carbonate, and sodium bicarbonate.
  • freshening agents include menthol, borneol, camphor, geraniol, limonene, eugenol, peppermint oil, eucalyptus oil, fennel oil, and bergamot oil.
  • solvents include sterilized purified water, purified water, and physiological saline.
  • the active ingredient is a peptide with an inhibitory effect against mitochondrial calpain, with a protein transduction domain added to the N-terminus.
  • 0.00001 to 100 mg is added per mL of eye drops, and by instilling one to several drops into the eye one to several times per day, the drug exerts preventive and therapeutic effects against age-related macular degeneration by protecting retinal pigment epithelial cells.
  • Example 1 Protective effect on retinal pigment epithelial cells of a peptide having an inhibitory effect on mitochondrial calpain with a protein transduction domain added to the N-terminus of the peptide (effect of administration to age-related macular degeneration model mice) Part 1 (Experimental Method) Using sodium iodate (SI)-administered mice (Investigative Ophthalmology & Visual Science, 58, 2239-2249, 2017), which are widely used as an experimental model for dry age-related macular degeneration, the eye drop effect of a peptide having an inhibitory effect against mitochondrial calpain and a protein transduction domain added to the N-terminus was evaluated.
  • SI sodium iodate
  • a peptide having an inhibitory effect on mitochondrial calpain and a protein transduction domain added to the N-terminus of the peptide (hereinafter abbreviated as "Tat- ⁇ CL peptide"; the same as ⁇ -N2-10-2 (HIV-N ⁇ ) peptide described in Japanese Patent No. 6183879) consisting of the amino acid sequence shown in SEQ ID NO: 6 (GRKKRRQRRRPPQPDALKSRTLR) was dissolved in physiological saline to a concentration of 20 mM and sterilized by filtration. The solution was pre-instilled in both eyes of a mouse (C57BL/6J, 8 weeks old) at 2 ⁇ L three times a day for 7 days.
  • a solution of SI dissolved in physiological saline and sterilized by filtration was administered intraperitoneally to administer 12.5 mg/kg of SI, and further, a solution of Tat- ⁇ CL peptide dissolved in physiological saline to a concentration of 20 mM and sterilized by filtration was pre-instilled in both eyes at 2 ⁇ L three times a day for 7 days. After 7 days, the mice were euthanized, both eyes were removed, and fixed in 4% paraformaldehyde, and the anterior segment and the lens were excised.
  • RPE retinal pigment epithelium cell layer
  • Figure 1 shows a tissue photograph of a retinal section
  • Figure 2 shows the results of measuring the number of deposits derived from the retinal pigment epithelium cell layer
  • Figure 3 shows the results of measuring the thickness of the retinal photoreceptor layer at positions approximately 300, 600, 900, 1200, and 1500 ⁇ m on the nasal and temporal sides, respectively, from the center of the optic disc (20 mM Tat- ⁇ CL
  • FIGS. 1 to 3 show the results of a similar experiment using a solution prepared by dissolving the Tat- ⁇ CL peptide in physiological saline to 20 mM and sterilizing the solution by filtration, instead of the solution prepared by dissolving the Tat- ⁇ CL peptide in physiological saline to 20 mM and sterilizing the solution by filtration, and using a peptide consisting of the amino acid sequence shown in SEQ ID NO: 7 (GRKKRRQRRRPPQASLRLDRPTK) in which the amino acid sequence of the ⁇ CL portion of the Tat- ⁇ CL peptide was randomly rearranged (hereinafter referred to as "Tat- ⁇ CL scrambled peptide”), and also show the results of a healthy mouse that had not been administered anything to the eyeball (none).
  • the Tat- ⁇ CL peptide effectively protected the retinal pigment epithelium cell layer by instillation at 20 mM.
  • the inhibition of thinning of the retinal photoreceptor layer by administration of the Tat- ⁇ CL peptide which is evident from FIG. 3, was considered to be a secondary effect due to the protection of the retinal pigment epithelium cell layer by the Tat- ⁇ CL peptide.
  • Example 2 Protective effect on retinal pigment epithelial cells of a peptide having an inhibitory effect on mitochondrial calpain with a protein transduction domain added to the N-terminus of the peptide (effect of administration to age-related macular degeneration model mice) Part 2 A solution in which Tat- ⁇ CL peptide was dissolved in physiological saline to 2 mM and sterilized by filtration, and a solution in which Tat- ⁇ CL scrambled peptide was dissolved in physiological saline to 2 mM and sterilized by filtration were used to carry out the same experiment as in Example 1.
  • Figure 4 shows a tissue photograph of a retinal section
  • Figure 5 shows the results of measuring the number of deposits derived from the retinal pigment epithelium cell layer
  • Figure 6 shows the results of measuring the thickness of the retinal photoreceptor cell layer at positions about 300, 600, 900, 1200, and 1500 ⁇ m from the center of the optic disc to the nasal side and the temporal side, respectively (none is the result of a healthy mouse that had not been administered any treatment to the eyeball).
  • Tat- ⁇ CL peptide effectively protected the retinal pigment epithelium cell layer and suppressed the thinning of the retinal photoreceptor cell layer even when instilled at 2 mM.
  • Example 3 Protective effect on retinal pigment epithelial cells of a peptide having an inhibitory effect on mitochondrial calpain with a protein transduction domain added to the N-terminus of the peptide (effect of administration to age-related macular degeneration model mice) Part 3 A similar experiment to that in Example 1 was carried out using a solution in which Tat- ⁇ CL peptide was dissolved in physiological saline to a concentration of 200 ⁇ M and sterilized by filtration, and a solution in which Tat- ⁇ CL scrambled peptide was dissolved in physiological saline to a concentration of 200 ⁇ M and sterilized by filtration.
  • Figure 7 shows a tissue photograph of a retinal section
  • Figure 8 shows the results of measuring the number of deposits derived from the retinal pigment epithelium cell layer
  • Figure 9 shows the results of measuring the thickness of the retinal photoreceptor cell layer at positions about 300, 600, 900, 1200, and 1500 ⁇ m from the center of the optic disc on the nasal side and the temporal side, respectively (none is the result of a healthy mouse that had not been administered any treatment to the eyeball).
  • Tat- ⁇ CL peptide effectively protected the retinal pigment epithelium cell layer and suppressed the thinning of the retinal photoreceptor cell layer even when instilled at 200 ⁇ M.
  • Tat- ⁇ CL peptide has a protective effect on retinal photoreceptor cells, but the concentration at which the effect could be confirmed by instillation was 40 mM.
  • Tat- ⁇ CL peptide could be confirmed to have a protective effect on retinal pigment epithelial cells by instillation at a concentration less than 1/100 of the concentration at which the protective effect on retinal photoreceptor cells by instillation could be confirmed, and it was demonstrated that a peptide having a protein transduction domain added to the N-terminus of a peptide having an inhibitory effect on mitochondrial calpain, such as Tat- ⁇ CL peptide, is useful for preventing and treating age-related macular degeneration in a non-invasive manner.
  • Example 4 Protective effect on retinal pigment epithelial cells of a peptide having a protein transduction domain added to the N-terminus of a peptide having an inhibitory effect on various mitochondrial calpains (effect of administration to the eyes of age-related macular degeneration model mice)
  • the following nine types of peptides were prepared by chemical synthesis using a peptide synthesizer, and each was dissolved in physiological saline to a concentration of 200 ⁇ M, followed by filtration sterilization, and then a similar experiment to that in Example 1 was carried out using the solution.
  • each of the peptides had a protective effect on retinal pigment epithelial cells when instilled at 200 ⁇ M, similar to the Tat- ⁇ CL peptide.
  • a peptide consisting of the amino acid sequence shown in SEQ ID NO:8 (GRKKRRQRRRPPQICNLTPDA LKSRTLR), in which the amino acid sequence of the ⁇ CL portion of the Tat- ⁇ CL peptide has been changed to an amino acid sequence in which 5 amino acids have been added to the N-terminus of the amino acid sequence (the amino acid sequence shown in SEQ ID NO:2)
  • a peptide consisting of the amino acid sequence shown in SEQ ID NO:9 GRKKRRQRRRPPQPDALKSRTLR NW
  • the amino acid sequence of the ⁇ CL portion of the Tat- ⁇ CL peptide has been changed to an amino acid sequence in which 5 amino acids have been added to the C-terminus of the amino acid sequence (the amino acid sequence shown in SEQ ID NO:3).
  • a peptide consisting of the amino acid sequence shown in SEQ ID NO:10 (GRKKRRQRRRPPQICNLTPDA LKSRTLR NWNTT) in which the amino acid sequence of the ⁇ CL portion of the Tat- ⁇ CL peptide has been changed to an amino acid sequence in which five amino acids have been added to each of the N-terminus and C-terminus of the amino acid sequence (the amino acid sequence shown in SEQ ID NO:4); a peptide consisting of the amino acid sequence shown in SEQ ID NO:11 (GRKKRRQRRRPPQICNLTPDA LKSRTLR NWNTT) in which the amino acid sequence of the ⁇ CL portion of the Tat- ⁇ CL peptide has been changed to an amino acid sequence in which two amino acids have been deleted from the N-terminus of the amino acid sequence a peptide consisting of the amino acid sequence (GRKKRRQRRRPPQPDALKSRT) shown in SEQ ID NO: 12, in which the amino acid sequence of the ⁇ CL portion of the Tat- ⁇ CL peptide
  • a peptide consisting of the amino acid sequence shown in SEQ ID NO: 15 (GRKKRRQRRRPPQPDALKSRTIR) in which the second leucine from the C-terminus of the amino acid sequence shown in SEQ ID NO: 1 has been replaced with isoleucine.
  • a peptide consisting of the amino acid sequence shown in SEQ ID NO: 16 (HHHHHHPDALKSRTLR) in which the amino acid sequence of the Tat portion of the Tat- ⁇ CL peptide has been changed to an amino acid sequence consisting of six histidines.
  • the present invention has industrial applicability in that it can provide a protective agent for retinal pigment epithelial cells that is useful for preventing and treating age-related macular degeneration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2024/035711 2023-10-11 2024-10-04 網膜色素上皮細胞の保護剤 Ceased WO2025079538A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025551481A JP7832745B2 (ja) 2023-10-11 2024-10-04 網膜色素上皮細胞の保護剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-175613 2023-10-11
JP2023175613 2023-10-11

Publications (1)

Publication Number Publication Date
WO2025079538A1 true WO2025079538A1 (ja) 2025-04-17

Family

ID=95395811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/035711 Ceased WO2025079538A1 (ja) 2023-10-11 2024-10-04 網膜色素上皮細胞の保護剤

Country Status (2)

Country Link
JP (1) JP7832745B2 (cg-RX-API-DMAC7.html)
WO (1) WO2025079538A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014047164A (ja) * 2012-08-31 2014-03-17 Hirosaki Univ 新規ペプチドおよびその医薬用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165181A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions for treatment of retinal detachment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014047164A (ja) * 2012-08-31 2014-03-17 Hirosaki Univ 新規ペプチドおよびその医薬用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DENG YANHUI, QIAO LIFENG, DU MINGYAN, QU CHAO, WAN LING, LI JIE, HUANG LULIN: "Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy", GENES & DISEASES, vol. 9, no. 1, 1 January 2022 (2022-01-01), NL , pages 62 - 79, XP093303083, ISSN: 2352-3042, DOI: 10.1016/j.gendis.2021.02.009 *
ZHANG SHUAISHUAI, QIU YINGZHE, FENG YUAN, ZHANG YI, LI YANAN, WANG BOXIN, WEI HELIANG, CHEN XILONG, SHEN LIXIA, LI WEI, ZHENG LIQI: "Calpain-2 Facilitates Autophagic/Lysosomal Defects and Apoptosis in ARPE-19 Cells and Rats Induced by Exosomes from RPE Cells under NaIO3 Stimulation", OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. 2023, 17 January 2023 (2023-01-17), US , pages 1 - 18, XP093303081, ISSN: 1942-0900, DOI: 10.1155/2023/3310621 *
尾崎拓, ミトコンドリアカルパインの生理機能の解明と加齢に伴う神経変性疾患に対する治療薬の創出, Hi!こちら岩手大学, 2021, vol. 47, p. 1, non-official translation (OZAKI, Taku, Elucidation of the physiological functions of mitochondrial calpain and development of therapeutic agents for age-related neurodegenerative diseases, Hi! Iwate University.) *

Also Published As

Publication number Publication date
JPWO2025079538A1 (cg-RX-API-DMAC7.html) 2025-04-17
JP7832745B2 (ja) 2026-03-18

Similar Documents

Publication Publication Date Title
JP3683595B2 (ja) セチリジン含有抗アレルギー点眼点鼻用組成物
JP5705552B2 (ja) 眼痛を処置または防止するためのケトロラックトロメタミン組成物
JP5244584B2 (ja) キサンタンガムおよびブドウ糖を含有する眼科用組成物
JP7695277B2 (ja) 安定なペプチド組成物
JP4682495B2 (ja) 眼疾患の予防、治療剤
EP0976407A1 (en) Antiseptic composition
JPWO2001017527A1 (ja) 眼疾患の予防、治療剤
KR101322527B1 (ko) 잔탄 검 및 테르페노이드를 포함하는 점안제
JP3502574B2 (ja) 眼感染症治療用眼軟膏剤
JP7832745B2 (ja) 網膜色素上皮細胞の保護剤
JP3876232B2 (ja) 眼科用製剤、点眼液、人工涙液、コンタクトレンズケアー用品、洗眼液、および眼軟膏
JP5735968B2 (ja) 眼痛を処置または予防するためのケトロラクトロメタミン組成物
CN106943590B (zh) 一种包含ngf的用于治疗角膜上皮损伤的药物组合物
KR102268002B1 (ko) 효과 지속성 점안제 조성물
WO2002040028A1 (fr) Gouttes pour les yeux en gel antibacterien
ES2902860T3 (es) Composiciones y métodos para el tratamiento de enfermedades oculares
CN107137698A (zh) 一种包含gdnf的用于治疗角膜上皮损伤的药物组合物
AU2017206626A1 (en) Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa
US20250161403A1 (en) Peptides and methods of use thereof in treating ocular disorders
KR20170021745A (ko) 티모신 β4 및 시트르산을 유효성분으로 포함하는 각막 손상 예방 또는 치료용 조성물
TWI901889B (zh) 胱胺的用途
RU2118523C1 (ru) Офтальмологическое средство преимущественно для лечения глаукомы
JP2000319194A (ja) 乾性角膜症治療剤
Laxson 13 Chapter Osmotic Agents
JP4982643B2 (ja) 眼科用医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24877134

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2025551481

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025551481

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE